Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

RegulatoryapprovedIMPAVIDO®Positive

AI Analysis

Summary

Eton Pharmaceuticals announced the U.S. commercial launch of IMPAVIDO® (miltefosine) capsules for treating rare diseases. This marks the availability of the drug in the U.S. market.

Outcome Details

U.S. commercial availability of IMPAVIDO® (miltefosine) capsules announced

Importance:5/10

Sentiment:

0.70

rare_diseasecommercial_launchcapsule_formulation

Related Companies

$ETON

Read the original article

Published by GlobeNewswire Pharma on September 28, 2026 10:50 AM

Read Original